Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04963088
Status:
UNKNOWN
Last Update Posted:
2021-07-15
First Post:
2021-06-21
Brief Title:
TISLELIZUMAB Combined With Anlotinib and ChemotherapyXELOX in the Treatment of Advanced Gastric Carcinoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
TISLELIZUMAB in Combination With Anlotinib and ChemotherapyXELOX as First-Line Treatment in Adults With Inoperable Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma
Status:
UNKNOWN
Status Verified Date:
2021-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TAXE-GC
Brief Summary:
This is a Phase 2 multi-cohort study to investigate safety anti-tumor activity of the monoclonal antibody BGB A317 in combination with Anlotinib and standard chemotherapy as first-line treatment in Gastric or Gastroesophageal Junction Carcinoma The study includes a screening up to 28 days treatment until disease progression intolerable toxicity or treatment withdrawal for another reason safety follow-up up to 30 days following last study drug treatment and survival follow-up phase
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None